We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Tepnel Gains Canadian IVD Approval of its Prenatal DNA Test for Chromosome Abnormalities

ELUCIGENE™ QST*R™ is a prenatal DNA-based diagnostic assay which detects common chromosome abnormalities.
News

TriPath Imaging Announces Receipt of BD Proposal

The proposal arose after a review by TriPath Imaging of potential strategic opportunities.
News

Tm Bioscience Completes Financing of Unsecured Subordinated Debentures and Warrants for Proceeds of $6.24 Million CDN

Proceeds from the financing will be used for the advancement of the Company's pipeline of genetic tests.
News

Digilab BioVisioN Continues Biomarker Cooperation with a Top 10 Pharmaceutical Company

Digilab BioVisioN and Novartis will continue and expand their cooperation in the field of biomarker discovery in drug treatment studies
News

The Pittsburgh Life Sciences Greenhouse Invests $100,000 for Achieving Improved Diagnosis of Disease

PLSG has invested $100,000 in RedPath Integrated Pathology, Inc.
News

First-Ever Genomic Test Predicts which Lung Cancer Patients Need Chemotherapy to Live

Duke Scientists Develop Test which has the Potential to Save Tens of Thousands of Lives Each Year
News

AstraZeneca and The University of Manchester Work with DxS on a Clinical Pharmacology Collaboration

Research project aims to assess correlation between circulating DNA and primary tumours.
News

Tepnel Announces Extension of Supply Agreement of Cystic Fibrosis Screening Kits

French Cystic Fibrosis Screening Programme renews its agreement to purchase ELUCIGENE™ Mutation Detection Kits for a further three years.
News

Genomic Test to Predict which Lung Cancer Patients Need Chemotherapy to Live

Patients with early-stage non-small cell lung cancer will receive the genomic test and its results will determine their treatment.
News

Tepnel Life Sciences Trading Update

Tepnel’s results for the 6 months ended 30 June 2006 will reflect continued strong top line sales growth.
Advertisement